Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes
Short-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secre...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2020-09, Vol.43 (9), p.2137-2145 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2145 |
|---|---|
| container_issue | 9 |
| container_start_page | 2137 |
| container_title | Diabetes care |
| container_volume | 43 |
| creator | Quast, Daniel R Schenker, Nina Menge, Björn A Nauck, Michael A Kapitza, Christoph Meier, Juris J |
| description | Short-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short-acting (lixisenatide) and long-acting (liraglutide) GLP-1 RAs.
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide. Changes from baseline in the number of reflux episodes during 24-h pH registration in the lower esophagus, lower esophagus sphincter pressure, gastric emptying (
C-sodium octanoate acid breath test), and gastric acid secretion (
C-calcium carbonate breath test) were analyzed.
Gastric emptying half-time was delayed by 52 min (Δ 95% CI 16, 88) with lixisenatide (
= 0.0065) and by 25 min (3, 46) with liraglutide (
= 0.025). There was no difference in the number of reflux episodes (mean ± SEM 33.7 ± 4.1 vs. 40.1 ± 5.3 for lixisenatide and liraglutide, respectively,
= 0.17) or the extent of gastroesophageal reflux (DeMeester score) (35.1 ± 6.7 vs. 39.7 ± 7.5,
= 0.61), with similar results for the individual GLP-1 RAs. No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed. Gastric acidity decreased significantly by -20.7% (-40.6, -0.8) (
= 0.042) with the GLP-1 RAs.
Lixisenatide exerted a more pronounced influence on gastric emptying after breakfast than liraglutide. Neither lixisenatide nor liraglutide had significant effects on esophageal reflux or motility. Gastric acid secretion appears to be slightly reduced by GLP-1 RAs. |
| doi_str_mv | 10.2337/dc20-0720 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2423060880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2444674103</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-7b7a699ab7553fd38ddc1a041a952a232ebf96c01e79286ac1c13a4b84e22dd93</originalsourceid><addsrcrecordid>eNpdkc1u1DAUhS0EotPCghdAlti0i4D_ktjLUZkOSJGooMAycpybjKuMHWxHap-mr1pP_xasrnTud-490kHoAyWfGef1l94wUpCakVdoRRUvi7IU8jVaESpUUSrFjtBxjNeEECGkfIuOOKtETUqxQnebYQCTIvYDbuyNjeB0sj3gPxDiErMW9DgtD9Lpr50PqcDa9bjxbizWJlk34m1zWVD8EwzMyQe8Hr2zMcUz7B3eRD_v9Ah6erBtdUzBGnyxuOzNe-vwZX4ILkf4a9MOX93OgBn-anUHCeI79GbQU4T3T_ME_b7YXJ1_K5of2-_n66YwXMhU1F2tK6V0V5clH3ou-95QTQTVqmSacQbdoCpDKNSKyUobaijXopMCGOt7xU_Q6ePdOfh_C8TU7m00ME3agV9iywTjpCJSkox--g-99ktwOV2mhKhqQQnP1NkjZYKPMcDQzsHudbhtKWkPrbWH1tpDa5n9-HRx6fbQv5DPNfF7NTqRkg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2444674103</pqid></control><display><type>article</type><title>Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Quast, Daniel R ; Schenker, Nina ; Menge, Björn A ; Nauck, Michael A ; Kapitza, Christoph ; Meier, Juris J</creator><creatorcontrib>Quast, Daniel R ; Schenker, Nina ; Menge, Björn A ; Nauck, Michael A ; Kapitza, Christoph ; Meier, Juris J</creatorcontrib><description>Short-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short-acting (lixisenatide) and long-acting (liraglutide) GLP-1 RAs.
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide. Changes from baseline in the number of reflux episodes during 24-h pH registration in the lower esophagus, lower esophagus sphincter pressure, gastric emptying (
C-sodium octanoate acid breath test), and gastric acid secretion (
C-calcium carbonate breath test) were analyzed.
Gastric emptying half-time was delayed by 52 min (Δ 95% CI 16, 88) with lixisenatide (
= 0.0065) and by 25 min (3, 46) with liraglutide (
= 0.025). There was no difference in the number of reflux episodes (mean ± SEM 33.7 ± 4.1 vs. 40.1 ± 5.3 for lixisenatide and liraglutide, respectively,
= 0.17) or the extent of gastroesophageal reflux (DeMeester score) (35.1 ± 6.7 vs. 39.7 ± 7.5,
= 0.61), with similar results for the individual GLP-1 RAs. No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed. Gastric acidity decreased significantly by -20.7% (-40.6, -0.8) (
= 0.042) with the GLP-1 RAs.
Lixisenatide exerted a more pronounced influence on gastric emptying after breakfast than liraglutide. Neither lixisenatide nor liraglutide had significant effects on esophageal reflux or motility. Gastric acid secretion appears to be slightly reduced by GLP-1 RAs.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc20-0720</identifier><identifier>PMID: 32647054</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Acidity ; Acids ; Adult ; Aged ; Agonists ; Antidiabetics ; Breath tests ; Calcium ; Calcium carbonate ; Deceleration ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - physiopathology ; Emptying ; Esophageal sphincter ; Esophagus ; Esophagus - drug effects ; Esophagus - physiopathology ; Female ; Gastric Acid - metabolism ; Gastric emptying ; Gastric Emptying - drug effects ; Gastric Emptying - physiology ; Gastric juice ; Gastroesophageal reflux ; Gastroesophageal Reflux - metabolism ; Gastroesophageal Reflux - physiopathology ; Gastroesophageal Reflux - prevention & control ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide-1 Receptor - agonists ; Humans ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Liraglutide - pharmacology ; Liraglutide - therapeutic use ; Male ; Middle Aged ; Motility ; Peptides - pharmacology ; Peptides - therapeutic use ; Receptors ; Research design ; Risk analysis ; Risk factors ; Secretion ; Sphincter</subject><ispartof>Diabetes care, 2020-09, Vol.43 (9), p.2137-2145</ispartof><rights>2020 by the American Diabetes Association.</rights><rights>Copyright American Diabetes Association Sep 1, 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-7b7a699ab7553fd38ddc1a041a952a232ebf96c01e79286ac1c13a4b84e22dd93</citedby><cites>FETCH-LOGICAL-c348t-7b7a699ab7553fd38ddc1a041a952a232ebf96c01e79286ac1c13a4b84e22dd93</cites><orcidid>0000-0003-4357-6846 ; 0000-0002-5835-8019</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32647054$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quast, Daniel R</creatorcontrib><creatorcontrib>Schenker, Nina</creatorcontrib><creatorcontrib>Menge, Björn A</creatorcontrib><creatorcontrib>Nauck, Michael A</creatorcontrib><creatorcontrib>Kapitza, Christoph</creatorcontrib><creatorcontrib>Meier, Juris J</creatorcontrib><title>Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Short-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short-acting (lixisenatide) and long-acting (liraglutide) GLP-1 RAs.
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide. Changes from baseline in the number of reflux episodes during 24-h pH registration in the lower esophagus, lower esophagus sphincter pressure, gastric emptying (
C-sodium octanoate acid breath test), and gastric acid secretion (
C-calcium carbonate breath test) were analyzed.
Gastric emptying half-time was delayed by 52 min (Δ 95% CI 16, 88) with lixisenatide (
= 0.0065) and by 25 min (3, 46) with liraglutide (
= 0.025). There was no difference in the number of reflux episodes (mean ± SEM 33.7 ± 4.1 vs. 40.1 ± 5.3 for lixisenatide and liraglutide, respectively,
= 0.17) or the extent of gastroesophageal reflux (DeMeester score) (35.1 ± 6.7 vs. 39.7 ± 7.5,
= 0.61), with similar results for the individual GLP-1 RAs. No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed. Gastric acidity decreased significantly by -20.7% (-40.6, -0.8) (
= 0.042) with the GLP-1 RAs.
Lixisenatide exerted a more pronounced influence on gastric emptying after breakfast than liraglutide. Neither lixisenatide nor liraglutide had significant effects on esophageal reflux or motility. Gastric acid secretion appears to be slightly reduced by GLP-1 RAs.</description><subject>Acidity</subject><subject>Acids</subject><subject>Adult</subject><subject>Aged</subject><subject>Agonists</subject><subject>Antidiabetics</subject><subject>Breath tests</subject><subject>Calcium</subject><subject>Calcium carbonate</subject><subject>Deceleration</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Emptying</subject><subject>Esophageal sphincter</subject><subject>Esophagus</subject><subject>Esophagus - drug effects</subject><subject>Esophagus - physiopathology</subject><subject>Female</subject><subject>Gastric Acid - metabolism</subject><subject>Gastric emptying</subject><subject>Gastric Emptying - drug effects</subject><subject>Gastric Emptying - physiology</subject><subject>Gastric juice</subject><subject>Gastroesophageal reflux</subject><subject>Gastroesophageal Reflux - metabolism</subject><subject>Gastroesophageal Reflux - physiopathology</subject><subject>Gastroesophageal Reflux - prevention & control</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide-1 Receptor - agonists</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Liraglutide - pharmacology</subject><subject>Liraglutide - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Motility</subject><subject>Peptides - pharmacology</subject><subject>Peptides - therapeutic use</subject><subject>Receptors</subject><subject>Research design</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Secretion</subject><subject>Sphincter</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1u1DAUhS0EotPCghdAlti0i4D_ktjLUZkOSJGooMAycpybjKuMHWxHap-mr1pP_xasrnTud-490kHoAyWfGef1l94wUpCakVdoRRUvi7IU8jVaESpUUSrFjtBxjNeEECGkfIuOOKtETUqxQnebYQCTIvYDbuyNjeB0sj3gPxDiErMW9DgtD9Lpr50PqcDa9bjxbizWJlk34m1zWVD8EwzMyQe8Hr2zMcUz7B3eRD_v9Ah6erBtdUzBGnyxuOzNe-vwZX4ILkf4a9MOX93OgBn-anUHCeI79GbQU4T3T_ME_b7YXJ1_K5of2-_n66YwXMhU1F2tK6V0V5clH3ou-95QTQTVqmSacQbdoCpDKNSKyUobaijXopMCGOt7xU_Q6ePdOfh_C8TU7m00ME3agV9iywTjpCJSkox--g-99ktwOV2mhKhqQQnP1NkjZYKPMcDQzsHudbhtKWkPrbWH1tpDa5n9-HRx6fbQv5DPNfF7NTqRkg</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Quast, Daniel R</creator><creator>Schenker, Nina</creator><creator>Menge, Björn A</creator><creator>Nauck, Michael A</creator><creator>Kapitza, Christoph</creator><creator>Meier, Juris J</creator><general>American Diabetes Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4357-6846</orcidid><orcidid>https://orcid.org/0000-0002-5835-8019</orcidid></search><sort><creationdate>202009</creationdate><title>Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes</title><author>Quast, Daniel R ; Schenker, Nina ; Menge, Björn A ; Nauck, Michael A ; Kapitza, Christoph ; Meier, Juris J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-7b7a699ab7553fd38ddc1a041a952a232ebf96c01e79286ac1c13a4b84e22dd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acidity</topic><topic>Acids</topic><topic>Adult</topic><topic>Aged</topic><topic>Agonists</topic><topic>Antidiabetics</topic><topic>Breath tests</topic><topic>Calcium</topic><topic>Calcium carbonate</topic><topic>Deceleration</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Emptying</topic><topic>Esophageal sphincter</topic><topic>Esophagus</topic><topic>Esophagus - drug effects</topic><topic>Esophagus - physiopathology</topic><topic>Female</topic><topic>Gastric Acid - metabolism</topic><topic>Gastric emptying</topic><topic>Gastric Emptying - drug effects</topic><topic>Gastric Emptying - physiology</topic><topic>Gastric juice</topic><topic>Gastroesophageal reflux</topic><topic>Gastroesophageal Reflux - metabolism</topic><topic>Gastroesophageal Reflux - physiopathology</topic><topic>Gastroesophageal Reflux - prevention & control</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide-1 Receptor - agonists</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Liraglutide - pharmacology</topic><topic>Liraglutide - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Motility</topic><topic>Peptides - pharmacology</topic><topic>Peptides - therapeutic use</topic><topic>Receptors</topic><topic>Research design</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Secretion</topic><topic>Sphincter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quast, Daniel R</creatorcontrib><creatorcontrib>Schenker, Nina</creatorcontrib><creatorcontrib>Menge, Björn A</creatorcontrib><creatorcontrib>Nauck, Michael A</creatorcontrib><creatorcontrib>Kapitza, Christoph</creatorcontrib><creatorcontrib>Meier, Juris J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quast, Daniel R</au><au>Schenker, Nina</au><au>Menge, Björn A</au><au>Nauck, Michael A</au><au>Kapitza, Christoph</au><au>Meier, Juris J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2020-09</date><risdate>2020</risdate><volume>43</volume><issue>9</issue><spage>2137</spage><epage>2145</epage><pages>2137-2145</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><abstract>Short-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short-acting (lixisenatide) and long-acting (liraglutide) GLP-1 RAs.
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide. Changes from baseline in the number of reflux episodes during 24-h pH registration in the lower esophagus, lower esophagus sphincter pressure, gastric emptying (
C-sodium octanoate acid breath test), and gastric acid secretion (
C-calcium carbonate breath test) were analyzed.
Gastric emptying half-time was delayed by 52 min (Δ 95% CI 16, 88) with lixisenatide (
= 0.0065) and by 25 min (3, 46) with liraglutide (
= 0.025). There was no difference in the number of reflux episodes (mean ± SEM 33.7 ± 4.1 vs. 40.1 ± 5.3 for lixisenatide and liraglutide, respectively,
= 0.17) or the extent of gastroesophageal reflux (DeMeester score) (35.1 ± 6.7 vs. 39.7 ± 7.5,
= 0.61), with similar results for the individual GLP-1 RAs. No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed. Gastric acidity decreased significantly by -20.7% (-40.6, -0.8) (
= 0.042) with the GLP-1 RAs.
Lixisenatide exerted a more pronounced influence on gastric emptying after breakfast than liraglutide. Neither lixisenatide nor liraglutide had significant effects on esophageal reflux or motility. Gastric acid secretion appears to be slightly reduced by GLP-1 RAs.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>32647054</pmid><doi>10.2337/dc20-0720</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4357-6846</orcidid><orcidid>https://orcid.org/0000-0002-5835-8019</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2020-09, Vol.43 (9), p.2137-2145 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2423060880 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Acidity Acids Adult Aged Agonists Antidiabetics Breath tests Calcium Calcium carbonate Deceleration Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - physiopathology Emptying Esophageal sphincter Esophagus Esophagus - drug effects Esophagus - physiopathology Female Gastric Acid - metabolism Gastric emptying Gastric Emptying - drug effects Gastric Emptying - physiology Gastric juice Gastroesophageal reflux Gastroesophageal Reflux - metabolism Gastroesophageal Reflux - physiopathology Gastroesophageal Reflux - prevention & control GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Liraglutide - pharmacology Liraglutide - therapeutic use Male Middle Aged Motility Peptides - pharmacology Peptides - therapeutic use Receptors Research design Risk analysis Risk factors Secretion Sphincter |
| title | Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A59%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Lixisenatide%20Versus%20Liraglutide%20(Short-%20and%20Long-Acting%20GLP-1%20Receptor%20Agonists)%20on%20Esophageal%20and%20Gastric%20Function%20in%20Patients%20With%20Type%202%20Diabetes&rft.jtitle=Diabetes%20care&rft.au=Quast,%20Daniel%20R&rft.date=2020-09&rft.volume=43&rft.issue=9&rft.spage=2137&rft.epage=2145&rft.pages=2137-2145&rft.issn=0149-5992&rft.eissn=1935-5548&rft_id=info:doi/10.2337/dc20-0720&rft_dat=%3Cproquest_cross%3E2444674103%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2444674103&rft_id=info:pmid/32647054&rfr_iscdi=true |